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Abstract
Background: Little is known about health-related quality of life (HRQoL) in pediatric patients with cardiac rhythm
devices. This study aims to compare self- and proxy-reported HRQoL in patients with pacemaker (PM) and
implantable cardioverter-defibrillator (ICD) to that in sex- and age-matched healthy controls and to examine
predictors for generic and disease-specific HRQoL.
Methods: The study included 72 PM and ICD patients (39% females) and 72 sex- and age-matched healthy controls
from 3 to 18 years of age. HRQoL data was obtained by the PedsQL 4.0 Generic Core Scales and Pediatric Cardiac
Quality of Life Inventory. Medical data was collected retrospectively from medical records.
Results: Patients had significantly lower self- and proxy-reported generic overall HRQoL and lower physical health
than healthy controls, and ICD patients also had lower psychosocial health. On multivariate analyses, generic overall
HRQoL and physical health was significantly predicted by current cardiac medication (β = −.39, p = .02 for overall
HRQoL, respectively β = −.44, p = .006 for physical health). Disease-specific overall HRQoL was only marginally
predicted by child age, device type, and the presence of a structural congenital heart disease (p < .10).
Conclusions: This study shows that PM and ICD patients have lower HRQoL than healthy controls and that
patients who need cardiac medication are seen by their parents at great risk for lower generic overall HRQoL. Our
study also indicates a trend towards higher risk for low disease-specific HRQoL in younger patients, ICD patients,
and patients with a structural congenital heart disease. Special attention should be given to these patients as they
may benefit from a timely clinical evaluation in order to provide supportive interventions.
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Background
Pacemakers (PMs) and implantable cardioverter-
defibrillators (ICDs) have proven to be life-saving
therapeutic options for the treatment of cardiac
arrhythmia. Over time, safer implant techniques and
smaller devices have been introduced, and today,
even very young patients can benefit from a perman-
ent cardiac rhythm device [1, 2]. In pediatric
patients, the most common indication for PM im-
plantation is post-operative or congenital advanced
atrioventricular block. The implantation of an ICD is
indicated for primary or secondary prevention of
sudden cardiac death caused by ventricular fibrilla-
tion or ventricular tachycardia, associated with con-
genital heart disease (CHD), genetic arrhythmia
syndromes, and cardiomyopathies [2, 3]. Both inter-
ventions face various challenges such as arrhythmia-
related symptoms, post-operative complications (e.g.
infections or pleural effusion), device-related compli-
cations (e.g. lead failure or battery depletion), and
regular outpatient visits for clinical and device
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examination. In fact, pediatric patients with PM or
ICD deal with life-long dependence on medical as-
sistance and must cope with restrictions in daily ac-
tivities and reduced life expectancy [4, 5]. This can
be very stressful and negatively impact their health-
related quality of life (HRQoL).
HRQoL is a multidimensional concept that evaluates
the subjective perception of the impact of health status on
physical, psychological, and social functioning and well-
being [6]. Knowledge of HRQoL is important and can help
to identify subjects who are at risk for health problems
and need professional assistance. Thus, it can be used to
adequately support patients in their adjustment to chronic
disease. Previously, few studies have described both gen-
eric and disease-specific HRQoL in pediatric patients with
PMs, with ICDs, or both [7–9]. The majority of studies
that used a generic HRQoL instrument indicated that pa-
tients with PMs or ICDs or both have lower HRQoL levels
than healthy controls [7–14]. However, medical risk fac-
tors for impaired HRQoL have not been studied systemat-
ically. One of these studies with PM and ICD patients
identified the presence of CHD and ICD as key drivers of
lower HRQoL [7]. Two studies found no association be-
tween generic HRQoL and cardiac illness severity in ICD
patients [8, 12], and one other study found left ventricular
ejection fraction lower than 55% and intake of cardiovas-
cular drugs associated with lower generic HRQoL [15].
The aims of this study were threefold. Firstly, we
wanted to compare self- and proxy-reported generic
HRQoL outcomes in PM and ICD patients to those in
sex- and age-matched healthy controls. Lower HRQoL
was expected in patients than in healthy controls.
Secondly, we wanted to describe the level of self- and
proxy-reported disease-specific HRQoL in PM and
ICD patients: We expected that ICD patients would
show lower HRQoL than PM patients. Thirdly, we
aimed to examine associations between patients’
socio-demographic and medical characteristics and
proxy-reported generic and disease-specific HRQoL.
Based on previous results [7], we expected to identify
lower HRQoL in ICD patients and in patients with
structural CHD.
Methods
Participants
This comparative cross-sectional study includes pediatric
cardiac rhythm device patients and sex- and age-
matched healthy controls from 3 to 18 years of age. All
PM and ICD patients, with or without complaints,
scheduled for regular follow-up visits at the cardiology
outpatient clinic of the University Children’s Hospital
Zurich between September 2015 and September 2016
were asked to participate in the study. Patients with PM
or ICD implantation within the last 3 months prior to
study were excluded to minimize the influence of acute
medical effects on HRQoL. Further exclusion criteria
were permanent residency outside Switzerland, lack of
German language fluency in patient or caregiver, refusal
to sign the informed consent, the presence of Down syn-
drome, and severe mental retardation. The healthy con-
trols were matched in age and sex and recruited via best
friends of the patients (40%), and advertisements placed
at the University of Zurich and community day care cen-
ters (60%). Interviews and standardized questionnaires
ensured that the controls had no chronic disease or cog-
nitive impairments. The study was approved by the Eth-
ical Review Board of the Canton of Zurich, Switzerland,
and was performed in full accordance with the Declar-
ation of Helsinki. All parents provided written informed
consent after the study procedures and aims had been
explained in detail. All pediatric patients provided verbal
assent, while adolescents older than 14 years of age also
provided written informed consent.
In total, 90 pediatric patients with PM or ICD were
eligible for study inclusion. Of these, 72 patients were
included (response rate 80%). Eighteen patients did
not participate, for the following reasons: lack of time
or interest (n = 13), lost to follow-up (n = 4), and
twins (n = 1; both twins took part in the study, but
only 1 child was randomly selected for inclusion in
the analysis, because parent-reported data on HRQoL
are correlated in such cases). Study participants did
not significantly differ from the 18 non-participants in
their sex (χ2 = .19, p = .79), age at study beginning
(U = -.98, p = .33), device type (χ2 = .02, p = .99), age at
initial device implantation (U = -.93, p = .35), presence
of structural CHD (χ2 = .18, p = .79), or total length of
cardiac hospitalization (U = -.80, p = .43).
Measurements
The time since initial device implantation (years) was
calculated by the difference between the child’s age at
HRQoL assessment and age at initial device implant-
ation. ICD patients were grouped by whether they had
experienced an aborted cardiac arrest or life-threatening
arrhythmia (secondary prevention) or not (primary pre-
vention) [16]. The severity of the disease in ICD patients
was defined by using the ICD severity index [12]. Pa-
tients with structural CHDs were categorized by the
complexity of the surgical repair into univentricular (i.e.
Fontan type) and biventricular physiology. Previous
open-heart surgery was dichotomized into yes or no.
The number of device-related post-initial-implant
surgeries was categorized into none, one, or more than
one. The length of each hospital stay related to cardiac
disease was summed into the total length of cardiac
hospitalization (days). Patients’ current cardiac medica-
tion was assessed by the intake of heart failure and/or
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antiarrhythmic medication, dichotomized into yes or no.
In addition, the presence of any other, non-cardiac
chronic disease (e.g. neurological diseases with recurrent
seizures) was noted.
Generic HRQoL was assessed using the validated and
authorized German version of the Pediatric Quality of
Life (PedsQL) 4.0 Generic Core Scales [17]. It is a widely
used 23-item measure for assessing HRQoL during the
past month by proxy-reports in the age range of 2 to 18
years and by child self-report in the age range of 5 to 18
years. This instrument encompasses the following 4 sub-
scales: physical functioning (8 items), social functioning
(5 items), emotional functioning (5 items), and school
functioning (5 items). The physical health summary
score is defined by the physical functioning subscale.
The psychosocial health summary score is computed as
the sum of the items over the number of items answered
in the emotional, social and school functioning sub-
scales. In addition, a total score (generic overall HRQoL)
can be computed as the sum of all the items divided by
the number of items answered on all subscales. Items
are reverse scored and linearly transformed to a 0–100
scale, with higher scores indicating better HRQoL.
Disease-specific HRQoL was assessed using an autho-
rized German version of the standardized Pediatric Cardiac
Quality of Life Inventory (PCQLI), which was supple-
mented by a preschool instrument [18, 19]. Thus, we used
the PCQLI consisting of two self-report versions (for ages
8–12 and 13–18) and three proxy-report versions (for ages
3–7, 8–12, and 13–18). Both self- and proxy-reported ver-
sions include 27 items (ages 8–12) and 38 items (ages 13–
18) comprising three subscales: ‘impact of disease’, ‘psycho-
social impact’, and ‘emotional environment’. A total score
for disease-specific overall HRQoL is calculated by the sum
of the ‘impact of disease’ and ‘psychosocial impact’ sub-
scales. The proxy-report version for preschool children
(ages 3–8) includes 52 items. A total score, computed by
the sum of all items, defines the overall disease-specific
HRQoL. All scales were linearly transformed into a 0–100
scale, with higher scores indicating better HRQoL. Cut-off
scores for very low, low, and normal disease-specific
HRQoL total scores are available calculated from a Ger-
man sample of 546 children with heart diseases [20].
The occurrence of major life events in the family dur-
ing the 12 months prior to assessment was assessed by
parental report, using a list of the following 12 life
events: birth of a child, divorce, marriage, person moving
into the household, significant change in family income,
indebtedness, relocation, job change of either parent, un-
employment of either parent, serious illness or accident
of a family member, death of family member or a close
friend, and child’s change of school [21]. A life event
score was computed by summing the number of life
events (range 0–12).
Child nationality and socioeconomic status (SES) were
assessed by a short parent-reported socio-demographic
questionnaire. SES was assessed by maternal education
and paternal occupation on a scale from 2 to 12, with 2
being the lowest and 12 the highest SES score. Three so-
cial classes were defined: lower (SES 2 to 5), middle (SES
6 to 9), and upper class (SES 10 to 12). This measure
has proven to be a valid indicator of SES in previous
studies involving the Swiss population [22].
Study procedure
After informed consent had been provided, HRQoL data
was obtained using standardized questionnaires. To as-
sess proxy-reports of child HRQoL from 3 to 18 years,
questionnaires were mailed to participating parents, who
completed them at home. Because valid and reliable self-
reported HRQoL data can be assessed from 7 to 8 years
of age [23], no self-reports were assessed for patients
younger than 7.5 years. For older patients, self-reported
HRQoL data was obtained in face-to-face interviews that
strictly followed the procedure in the questionnaire. To
ensure that the patients could express their own views
openly, they were interviewed separately from their par-
ents. The interviews were conducted by the first, second,
or third author, all of whom had been trained. Self- and
proxy-reported HRQoL data was assessed within 2
weeks. Patients’ medical data was collected retrospect-
ively from medical records.
Statistical analyses
Data were analyzed using the SPSS statistical package,
release 22.0 for Windows (SPSS Inc., Chicago, IL, USA).
All statistical tests were two-sided with a predefined sig-
nificance level of p < .05. Chi-square tests and Mann-
Whitney U-tests were used, as appropriate, to compare
child sex, age at study beginning, device type, age at de-
vice implantation, the presence of structural CHD and
the total length of cardiac hospitalization between study
participants and non-participants. The differences in
generic HRQoL between patient sample and control
group and between self- and proxy-reports were ana-
lyzed by testing first the interaction between study group
(patient vs. control) and report (self vs. proxy), and then
the differences between patient and control group on
one side and between self- and proxy-reports on the
other side (see caption of Table 2). Associations between
medical variables and generic and disease-specific
HRQoL scores (self- and proxy-reports) were measured
by non-parametric Kendall’s rank correlation coeffi-
cients. Because some medical variables were continuous
while others were categorical or dichotomous, we de-
cided to use this coefficient in all cases. Four separate
multiple linear regression models with identical variables
were used to predict HRQoL (with the generic overall
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HRQoL score, the physical health and psychosocial
health summary score, and the disease-specific overall
HRQoL score as dependent variables). Selection of pre-
dictors was based on a priori hypotheses and on the stat-
istical significance of bivariate correlations with the total
score. Eight predictors were entered: child sex, age at as-
sessment (years), time since initial device implantation
(years), device type, structural CHD, current cardiac
medication, total length of cardiac hospitalization (days),
and other non-cardiac chronic disease. The absence of
multi-collinearity was confirmed by examining the cor-
relation matrix (correlations > .80) and the variance in-
flation factor [24].
Results
Patient socio-demographic and medical characteristics
for the total sample and the two device types are sum-
marized in Table 1. The majority of the patients (82%)
had a PM device, while 13 patients (18%) had an ICD.
Patients with an ICD were significantly older at assess-
ment and initial device implantation than patients with
PM. Four of the 59 PM patients (7%) and 5 of the 13
ICD patients (39%) had experienced resuscitation before
implantation. Overall, 40 of the 72 PM and ICD patients
(56%) had a CHD, and 33 of these (83%) had also under-
gone open-heart surgery. The time since last device-
related surgery was significantly shorter in ICD patients
than in PM patients, andICD patients needed more anti-
arrhythmic medication than PM patients. In total, drug
therapy for heart failure or arrhythmia was present in 23
of 72 patients (32.9%), with 3 patients (4.2%) who
needed both medications, 14 patients (19.4%) antiar-
rhythmic medication only, and 3 patients (4.2%) heart
failure medication only. An additional non-cardiac
chronic disease was present in 13 of 72 patients (18%):
attention deficit hyperactivity disorder (n = 3), hearing
disorder (n = 1), congenital hand or arm malformation
(n = 2), diabetes mellitus (n = 1), neurological disease
(n = 5), and diseases of the endocrine system (n = 1).
The sex- and age-matched healthy controls did not
differ significantly from the patient sample in Swiss na-
tionality (patient group: 82%; control group: 83%). In
contrast, controls had significantly higher SES: 33 of the
72 controls (46%) belonged to the upper SES class, but
only 17 of the 72 patients (24%) did. Furthermore, par-
ents of patients reported having experienced more previ-
ous life events than parents of controls (p < .001; patient
group: M = 2.2, SD = 1.9, range = 0–7; control group:
M = 0.8, SD = 1.0, range = 0–4). In both samples, death
of a family member or a close friend (patient sample:
39%, control group: 18%) and a job change of either par-
ent (patient sample: 34%, control group: 21%) were the
most frequently reported life events.
Mean values of self- and proxy-reported generic
HRQoL scores for the patient sample and control group
are presented in Table 2 separately for the PM and ICD
groups. None of the interactions between study group
(patient vs. control group) and report (self vs. proxy)
was significant. This means that average HRQoL differ-
ences between patients and controls are the same for
self- and proxy-reported HRQoL data. Our analyses
showed that parents of PM and ICD patients reported
significantly lower overall HRQoL and lower physical
health summary scores than did parents of healthy con-
trols. In addition, parents of ICD patients reported lower
psychosocial health summary scores. No significant dif-
ferences were found between self- and proxy-reported
generic HRQoL scores.
The number of patients with very low, low, and nor-
mal disease-specific HRQoL (proxy- and self-reported
data) are indicated in Fig. 1. The majority of the patients
have normal proxy- and self-reported disease-specific
HRQoL. Chi-square tests revealed that ICD patients
more frequently had very low proxy-reported disease-
specific HRQoL than did PM patients (χ2 = 10.7,
p = .005). No such difference was found in the self-
reported data between PM and ICD patients (χ2 = 1.01,
p = .60). Among ICD patients, 25% of the parents re-
ported very low disease-specific HRQoL for their child,
while no patient reported very low and 9% reported low
disease-specific HRQoL. Thus, significant differences be-
tween self- and proxy-reported disease-specific HRQoL
scores were found in all subscales and the total score
(p = .002, d = −.47).
Associations between generic or disease-specific HRQoL
scores and socio-demographic and medical characteristics
are presented in Table 3. Kendall correlation coefficients
showed that generic HRQoL scores were not significantly
associated with patients’ socio-demographic characteris-
tics, while it was associated with current cardiac medica-
tion. Disease-specific HRQoL scores were significantly
associated with child age at assessment, the presence of a
structural CHD and a longer total length of cardiac
hospitalization.
Table 4 summarizes the results of four separate mul-
tiple regression analyses predicting proxy-reported gen-
eric and disease-specific HRQoL (generic overall HRQoL
score, physical health and psychosocial health summary,
and disease-specific overall HRQoL). In regression
models predicting generic HRQoL, child sex and age
were not significant predictors. Among the medical vari-
ables, current cardiac medication was a significant pre-
dictor for overall HRQoL and the physical health
summary score, while no significant association was
found with the psychosocial health summary score. The
need for cardiac medication was associated with lower
generic overall HRQoL and physical health. In addition,
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Table 1 Patient socio-demographic and medical characteristics by cardiac rhythm device type
Total sample
(n = 72)
PM
(n = 59)
ICD
(n = 13)
Comparison:
PM vs. ICD group
p value†
Female sex, n (%) 28 (39) 25 (42) 3 (23) .23
Age at assessment (years), mean (SD), range 11.3 (4.6), 3.2–18.0 10.5 (4.4), 3.2–17.9 14.9 (3.2), 7.6–18.0 <.001
Swiss nationality, n (%) 59 (82) 47 (80) 12 (92) .44
Socio-economic status, n (%) .23
Lower class 3 (4) 3 (6) 0
Middle class 49 (68) 38 (64) 11 (84)
Upper class 17 (24) 16 (27) 1 (8)
Unknown 3 (4) 2 (3) 1 (8)
Number of previous life events, mean (SD), range 2.2 (1.9), 0–7 2.3 (2.0), 0–7 1.7 (1.3), 0–4 .44
Age at initial device implant (years), mean (SD), range 4.7 (4.4), 0–15.3 3.5 (3.5), 0–12.6 9.8 (4.0), 2.9–15.3 <.001
Newborn (age≤ 28 days), n (%) 7 (10) 7 (12) 0
Infant/toddler (29 days to 3 years), n (%) 23 (32) 22 (37) 1 (8)
Preschool (3 to 6 years), n (%) 18 (25) 17 (29) 1 (8)
School-age (6 to 13 years), n (%) 21 (29) 13 (22) 8 (62)
Adolescent (age > 13 years), n (%) 3 (4) 0 3 (23)
Time since initial device implant (years), mean
(SD), range
6.7 (4.5), 0.4–17.9 7.1 (4.6), 0.4–17.9 5.1 (3.9), 0.5–12.7 .23
Device system, n (%)
Single-chamber 9 (13) 4 (7) 5 (39)
Dual-chamber 63 (87) 55 (93) 8 (61) .002
Location of electrode, n (%)
Epicardial 69 (96) 59 (100) 10 (77)
Endocardial 3 (4) 0 3 (23) NA
Electrophysiological disease, n (%)
Postoperative heart block 20 (28) 20 (34)
Congenital heart block 25 (35) 25 (42)
Sinoatrial node disease 14 (19) 14 (24)
Ventricular tachycardia or fibrillationa 13 (18) 13 (100) NA
ICD indication, n (%)
Primary prevention NA NA 7 (54)
Secondary prevention NA NA 6 (46) NA
ICD Severity Index, mean (SD), range NA NA 8.0 (3.8), 3–16 NA
Structural congenital heart disease, n (%)
Biventricular physiology 34 (47) 26 (44) 8 (61)
Univentricular physiology 6 (8) 6 (10) 0
No structural congenital heart disease 32 (45) 27 (46) 5 (39) .34
Previous open heart surgery, n (%) 33 (46) 30 (51) 3 (23) .07
Number of device-related post-initial-implant
surgeries, n (%)
None 38 (53) 33 (56) 5 (39)
One 21 (29) 15 (25) 6 (46)
More than one 13 (18) 11 (19) 2 (15) .25
Time since last device-related surgery (years),
mean (SD), range
3.5 (2.6), 0.3–12.7 3.9 (2.6), 0.3–12.7 1.8 (1.5), 0.3–5.4 .004
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Table 1 Patient socio-demographic and medical characteristics by cardiac rhythm device type (Continued)
Total sample
(n = 72)
PM
(n = 59)
ICD
(n = 13)
Comparison:
PM vs. ICD group
p value†
Total length of cardiac hospitalization (days),
mean (SD), range
52.4 (32.5), 2–266 57.0 (62.4), 2–266 31.5 (33.0), 3–133 .26
Current cardiac medication
Antiarrhythmic, n (%) 17 (24) 7 (12) 10 (77) <.001
Heart failure, n (%) 6 (8) 5 (9) 1 (8) .93
Other non-cardiac chronic disease, n (%) 13 (18) 9 (15) 4 (31) .19
NA Not applicable, PM Pacemaker, ICD Implantable cardioverter-defibrillator
† Chi square tests or Mann-Whitney-U tests were performed
a Patients with documented ventricular tachycardia or fibrillation or with a significant risk of ventricular tachycardia or fibrillation
Significant values are indicated in bold
Table 2 Sample means for generic health-related quality of life in pediatric patients with PM/ICD and their controls: comparison
between patients and control group and between self- and proxy report
Parent proxy-report form Child self-report form Interaction:
Study
group
(patient/
control) vs.
report
(self/proxy)
Differences
Patient sample
vs. control
group
(all control –
patient
differences)
Differences
Self- vs. proxy
report
(all self – proxy
differences)
Patient sample Control
group
Patient sample Control
group
Device
type
n M (SD) n M (SD) Device
type
n M (SD) n M (SD) p- value† M (SD) p-
value
M (SD) p-
value
PedsQL scales
Total Score PM 57 83.0
(14.5)
59 89.9
(8.1)
PM 39 82.1
(11.6)
42 86.7
(12.2)
.34 7.1
(17.8)
.007 −1.3
(9.8)
.21
Physical Health
Summary
PM 57 86.4
(16.5)
59 94.6
(8.5)
PM 39 84.0
(13.9)
42 87.6
(14.2)
.24 8.7
(18.4)
≤.001 −2.8
(12.6)
.06
Psychosocial Health
Summary
PM 57 79.6
(14.3)
59 85.1
(9.6)
PM 39 80.3
(11.6)
42 85.8
(11.9)
.85 5.4
(19.0)
.057 0.1
(12.5)
.78
Emotional
Functioning
PM 57 73.2
(17.2)
59 75.6
(15.1)
PM 39 76.5
(16.6)
42 82.5
(12.8)
.26 2.2
(26.1)
.69 1.5
(16.3)
.93
Social Functioning PM 57 85.9
(19.2)
59 91.0
(11.9)
PM 39 84.6
(13.6)
42 90.0
(15.5)
.84 5.0
(23.4)
.16 −1.1
(13.9)
.94
School Functioning PM 55 80.1
(17.1)
56 88.7
(12.2)
PM 39 79.6
(13.4)
42 84.8
(14.1)
.43 9.4
(20.5)
.002 0.0
(18.9)
.41
PedsQL scales
Total Score ICD 13 75.8
(16.0)
13 92.2
(7.0)
ICD 12 77.7
(14.9)
13 91.0
(7.2)
.16 16.4
(15.1)
.009 2.1
(17.5)
.41
Physical Health
Summary
ICD 13 76.0
(17.4)
13 95.9
(5.9)
ICD 12 76.0
(19.8)
13 90.1
(9.4)
.17 20.0
(16.5)
.005 −0.3
(22.8)
.53
Psychosocial Health
Summary
ICD 13 75.6
(16.8)
13 88.6
(11.3)
ICD 12 79.4
(12.2)
13 91.8
(5.7)
.75 12.9
(17.8)
.02 4.4
(15.0)
.33
Emotional
Functioning
ICD 13 72.3
(23.3)
13 84.6
(14.1)
ICD 12 79.2
(14.4)
13 89.2
(9.8)
.62 12.3
(21.4)
.06 7.1
(17.9)
.21
Social Functioning ICD 13 80.4
(19.1)
13 93.5
(11.3)
ICD 12 82.5
(13.7)
13 95.4
(8.3)
.79 13.1
(21.5)
.06 1.7
(22.4)
.39
School Functioning ICD 13 74.2
(18.0)
13 87.7
(13.0)
ICD 12 76.7
(15.1)
13 90.8
(7.9)
.88 13.5
(21.4)
.06 4.6
(18.6)
.73
Higher scores indicate better health-related quality of life
PedsQL Pediatric quality of life inventory, PM Pacemaker, ICD Implantable cardioverter defibrillator
† Calculation for the interaction: Let YPPr, YCPr, YPS, YCS define HRQoL of the patients and controls for self- and proxy reports, respectively. Then the difference (YPPr-
YCPr) – (YPS-YCS) was calculated and tested against 0 by Wilcoxon test
Significant values are indicated in bold
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the presence of another non-cardiac chronic disease was
associated with lower physical health. Disease-specific
overall HRQoL was only marginally associated with child
age at assessment, device type, and structural CHD
(p < .10). Younger patients, patients with ICD, and those
with a structural CHD had lower disease-specific
HRQoL than older patients, patients with PM, and those
with no CHD.
Discussion
This study shows that pediatric PM and ICD patients
have lower generic HRQoL than age- and sex-matched
healthy controls, and that patients who need cardiac
medication are seen as being at great risk for reduced
generic HRQoL. The study also shows that the major-
ity of the patients have normal proxy- and self-
reported disease-specific HRQoL. Further, younger
Fig. 1 Number of pacemaker (PM) and implantable cardioverter-defibrillator (ICD) patients with very low, low, and normal disease-specific health-
related quality of life (HRQoL) assessed by the Pediatric Cardiac Quality of Life Inventory (PCQLI)
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patients, patients with ICDs, and those with a struc-
tural CHD may have a higher risk for lower proxy-
reported disease-specific HRQoL.
In line with our hypothesis and with previous studies
with PM patients, ICD patients, or both [7, 8, 10–13],
pediatric PM and ICD patients showed lower self- and
proxy-reported overall HRQoL and lower physical health
than sex- and age-matched healthy controls. Lower psy-
chosocial health was only found in ICD patients. In our
study, healthy controls had higher SES and had experi-
enced fewer previous life events than the patients. Con-
sequently, we examined whether these variables might
influence the HRQoL differences between patients and
controls. A multiple linear regression with generic over-
all HRQoL differences as dependent variable showed no
significant effect of SES or of number of previous life
events on HRQoL differences between patients and con-
trols (data not shown). A multitude of risk factors might
influence the significant HRQoL differences between pa-
tients and controls (e.g. mental disorder of a parent,
marital disharmony, lack of social support [25]). How-
ever, PM and ICD patients have to cope with at least
one more life event than do healthy controls. The pres-
ence of a chronic disease with associated challenges such
as arrhythmia-related symptoms, post-operative compli-
cations, device-related complications, and regular out-
patient visits for clinical and device examination, which
might be experienced as a threat exceeding the resources
of the patients and their families [26] might be reflected
in reduced HRQoL. Our study showed that parents of
20% of the patients and 7% of the patients themselves
reported very low or low disease-specific HRQoL. Thus,
some PM and ICD patients are at great risk for low
HRQoL. Our data shows that parents and patients re-
ported about the same level of generic HRQoL, while
parents reported lower disease-specific HRQoL than the
patients themselves. Thus, we may assume that the par-
ents’ subjective experience of the child’s disease may es-
pecially bias their disease-specific proxy-reports.
In multivariate analyses, generic and disease-specific
HRQoL were not predicted by the same variables. This
probably reflects the scope of the questionnaires used.
We decided to use the PedsQL 4.0 Generic Core scales
[17] and the PCQLI [18, 19]. While the PedsQL as-
sesses the full range of health conditions (physical, so-
cial, emotional, and school functioning) and can be
used to report HRQoL independently of the actual
health state of the individual [27], the PCQLI refers to
the unique challenges of a heart disease [27] and, thus,
may more comprehensively report the challenges faced
by PM and ICD patients [28]. This is also shown by the
higher percentage of total variance explained by the
predictors selected for disease-specific HRQoL. Our
study showed that the need for antiarrhythmic or heart
failure medication was associated with lower generic
overall HRQoL and physical health. This finding is in
line with the only previous study which analyzed the as-
sociation between medication and HRQoL exclusively
Table 3 Inter-correlations between total generic and disease-specific HRQoL scores (proxy-report form) and child socio-
demographic and medical characteristics
All patients (n = 66 to 72)
1 2 3 4 5 6 7 8 9 10 11 12 13
1. Total generic HRQoL –
2. Total disease-specific HRQoL .48*** –
3. Female sex −.03 −.06 –
4. Age at assessment (years) .02 .24** −.07 –
5. Swiss nationality .10 .12 .00 .18 –
6. Socio-economic status .06 .07 .19 −.17 .21 –
7. Number of previous life events −.13 −.08 .00 .11 −.17 .03 –
8. Time since initial device implant (years) −.01 .15 −.02 .38*** .02 −.10 .31*** –
9. Device type (PM or ICD) .16 .16 .15 −.32*** −.13 .13 .08 .12 –
10. Structural congenital heart disease −.15 −.35*** −.09 −.16 .02 −.13 −.09 .05 −.06 –
11. Current cardiac medication −.33*** −.31** −.18 .11 .13 −.07 −.20 −.12 −.60*** .24* –
12. Total length of cardiac hospitalization (days) −.13 −.21* −.08 −.15 −.03 −.07 −.08 .14 .11 .57*** .21* –
13. Previous open heart surgery −.03 −.17 −.05 −.15 −.00 −.09 −.12 .09 .21 .82*** .11 .59*** –
14. Other non-cardiac chronic disease −.19 −.07 −.08 .18 .13 .19 .20 .17 −.16 −.02 .11 −.00 −.14
Kendall correlation coefficients are presented
Device type coded as 0 = ICD, 1 = PM; Structural congenital heart disease coded as 0 = no, 1 = yes; Current cardiac medication coded as 0 = no, 1 = yes; Previous
open heart surgery coded as 0 = no, 1 = yes; Other chronic disease coded as 0 = no, 1 = yes (any other chronic disease than heart disease)
HRQoL Health-related quality of life
* p ≤ .05, ** p ≤ .01, *** p ≤ .001
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in PM patients [15]. Thus, pediatric PM and ICD pa-
tients who take medication are seen as being at risk for
lower generic HRQoL by their parents. Three hypoth-
eses are close: First, it could be assumed that these
patients have greater disease-related problems than pa-
tients without medication. Second, it might be possible
that these patients already had a lower HRQoL before
the onset of their arrhythmia and that patients with low
HRQoL are more likely to be prescribed medication.
Third, it might be that the intake of medication re-
minds the patients and their parents of the disease,
which can be reflected in lower HRQoL scores. How-
ever, in the context of this study, we were not able to
prove these hypotheses and whether medication is an
intermediating factor or not. Future studies might ad-
dress this. Disease-specific HRQoL was only marginally
predicted by child age, device type, and structural
CHD. Younger patients, patients with ICDs, and those
with CHD tended to have lower disease-specific
HRQoL than older patients, patients with PM, and
those without CHD. This result is in line with a previ-
ous study’s finding that patients with ICD and a struc-
tural CHD have lower HRQoL [7].
The strengths of the current study include the use of
standardized and well-validated HRQoL instruments and
the presentation of data on both generic and disease-
specific HRQoL, which are seen as essential comple-
ments to each other [23] and which allow the influence
of medical risk factors on each to be compared. Never-
theless, several limitations merit note. First, even though
we achieved a response rate of 80% and our analyses re-
vealed no significant differences between study partici-
pants and non-participants in sex, age at study
beginning, device type, age at initial device implantation,
presence of structural CHD, or the total length of car-
diac hospitalization, we cannot exclude the possibility
that the patients who participated in our study differed
with respect to other variables (e.g. HRQoL) from those
who did not. In addition, the possibility that some cross-
contamination occurred between patients and controls
Table 4 Summary of multiple linear regression analyses predicting proxy-reported generic and disease-specific HRQoL of patients
with PM/ICD
Generic HRQoL Generic overall HRQoL (n = 70) Physical Health Summary Psychosocial Health Summary
Predictor variable B SEB β t p B SEB β t p B SEB β t p
Female sex −2.98 3.49 −.10 −.86 .40 −4.54 3.91 −.13 − 1.16 .25 −1.43 3.59 −.05 −.40 .69
Age at assessment (years) .47 .55 .14 .85 .39 .33 .62 .09 .53 .60 .61 .57 .19 1.08 .29
Time since initial device implant (years) −.66 .53 −.19 −1.25 .22 −.64 .59 −.17 − 1.08 .28 −.67 .54 −.20 −1.24 .22
Device type (PM or ICD) 2.12 6.35 .06 .33 .74 2.01 7.11 .05 .28 .78 2.23 6.53 .06 .34 .73
Structural congenital heart disease 2.69 4.10 .09 .66 .51 3.46 4.59 .10 .75 .45 1.93 4.21 .07 .46 .65
Current cardiac medication −12.73 5.14 −.39 −2.48 .02 −16.45 5.75 −.44 −2.86 .006 −9.02 5.28 −.28 −1.71 .09
Total length of cardiac hospitalization (days) −.05 .04 −.18 −1.27 .21 −.04 .04 −.13 −.93 .36 −.06 .04 −.22 −1.45 .15
Other non-cardiac chronic disease −8.69 4.50 −.22 −1.93 .06 −10.20 5.04 −.23 −2.03 .05 −7.19 4.62 −.19 −1.56 .13
F = 2.78, p = .01, R2 = .27,
R2adjusted = .17
F = 3.11, p = .005, R2 = .29,
R2adjusted = .20
F = 1.93, p = .07, R2 = .20,
R2adjusted = .10
Disease-specific HRQoL Disease-specific overall HRQoL
(n = 66)
Predictor variable B SEB β t p
Female sex −4.14 3.54 −.13 −1.17 .25
Age at assessment (years) 1.06 .55 .31 1.91 .06
Time since initial device implant (years) .06 .53 .02 .10 .92
Device type (PM or ICD) 12.03 6.43 .29 1.87 .07
Structural congenital heart disease −7.72 4.21 −.24 −1.83 .07
Current cardiac medication −4.50 5.10 −.13 −.88 .38
Total length of cardiac hospitalization (days) −.04 .04 −.14 −.98 .33
Other non-cardiac chronic disease −5.88 4.50 −.14 −1.31 .20
F = 4.17, p≤ .001, R2 = .37,
R2adjusted = .28
Device type coded as 0 = ICD, 1 = PM; Structural congenital heart disease coded as 0 = no, 1 = yes; Current cardiac medication coded as 0 = no, 1 = yes; Other
chronic disease coded as 0 = no, 1 = yes (any other chronic disease than heart disease)
B Regression coefficient (unstandardized), SEB Standard error of the regression coefficient, β Standardized regression coefficient
Significant values are indicated in bold
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cannot be excluded, since 40% of controls were recruited
via patients’ best friends. Second, the cross-sectional de-
sign of our study prevents us from drawing any conclu-
sion about causal relations, and we are not able to
describe the course of HRQoL over time. Third, our
study included a rather small number of ICD patients,
making it difficult to compare both device groups with
respect to socio-demographic and medical characteris-
tics. In terms of a post-hoc power analysis (α = .05, two-
tailed) using G*power software [29], our sample size
provided sufficient power to detect moderate effect sizes
within the multiple regression analysis predicting proxy-
reported generic and disease-specific HRQoL. However,
we were not able to predict self-reported generic and
disease-specific HRQoL. Fourth, our study shows that
socio-demographic and medical factors explain only a
relatively small proportion of the patients’ HRQoL out-
come variance. This seems to imply that other factors
not assessed in the current study influence the patients’
HRQoL. In fact, we were unable to provide data on pa-
tients’ social support or parental well-being or to define
its proportion of variance explaining either generic or
disease-specific HRQoL.
Conclusions
Our study shows that PM and ICD patients have lower
generic overall HRQoL compared to healthy controls
and that patients who need cardiac medication are at
great risk for lower generic HRQoL. Furthermore, our
study indicated a trend towards higher risk for low
disease-specific HRQoL in younger patients, ICD pa-
tients, and patients with a structural CHD. Special atten-
tion should be given to these patients. They may benefit
from a timely clinical evaluation of their HRQoL in
order to provide supportive interventions.
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